Ophthalmic NSAID gains expanded indication


The FDA has approved ISTA's supplemental New Drug Application (sNDA) for Xibrom (bromfenac topical ophthalmic solution) 0.09%, expanding Xibrom's indications to include the treatment of pain following cataract surgery. Xibrom, a topical, twice-daily NSAID, was originally approved by the FDA in March 2005 for the treatment of ocular inflammation following cataract surgery.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.